Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain

Patient-reported health-related quality of life, work productivity, and activity impairment during treatment with ALO-02 (extended-release oxycodone and sequestered naltrexone) for moderate-to-severe chronic low back pain

Abstract Background The efficacy of ALO-02, an abuse-deterrent formulation containing extended-release oxycodone and sequestered naltrexone, in the treatment of chronic low back pain (CLBP) was studied in a 12-week randomized controlled trial. Primary efficacy endpoint results have been published pr...

Full description

Bibliographic Details
Main Authors: Arnold J. Weil, Elizabeth T. Masters, Alexandra I. Barsdorf, Almasa Bass, Glenn Pixton, Jacquelyn G. Wilson, Gernot Wolfram
Format: Article
Language:English
Published: BMC 2017-10-01
Series:Health and Quality of Life Outcomes
Subjects:
Abuse-deterrent opioids
Patient-reported outcomes
Chronic low back pain
Naltrexone
Oxycodone and extended-release opioid
Online Access:http://link.springer.com/article/10.1186/s12955-017-0749-y

Similar Items

Similar Items